Q-omics provides the consensus-scored MIR4436A profile across patient tissues and cancer cell-line models. MIR4436A expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MIR4436A is differentially expressed in 2, with the highest sampling consensus in LUAD. Additionally, MIR4436A RNA expression shows 8,789 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, LUAD, and THYM as cancer lineages where MIR4436A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR4436A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR4436A survival associations across molecular data types. MIR4436A RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR4436A RNA expression–survival associations across cancer types. High MIR4436A expression shows unfavorable associations in UVM, STAD, LUSC, THCA and UCS, but favorable associations in PAAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for MIR4436A RNA expression.
This table summarizes MIR4436A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for MIR4436A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR4436A shows lower tumor expression in COAD and higher tumor expression in LUAD. The LUAD box plot shows higher MIR4436A RNA expression in tumor versus normal tissue (log2 FC = +0.157, t-test p = .028).
This table shows molecular features associated with MIR4436A in patient tissues and cancer cell lines. In patient samples, MIR4436A shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
